Free Trial

Avalon GloboCare (ALBT) Stock Price, News & Analysis

-0.02 (-6.55%)
(As of 05/29/2024 ET)
Today's Range
50-Day Range
52-Week Range
206,628 shs
Average Volume
139,593 shs
Market Capitalization
$3.17 million
P/E Ratio
Dividend Yield
Price Target
ALBT stock logo

About Avalon GloboCare Stock (NASDAQ:ALBT)

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

ALBT Stock Price History

ALBT Stock News Headlines

Avalon GloboCare Corp. (ALBT)
Avalon GloboCare launches KetoAir breathalyzer in the US
Avalon Globocare Corp ALBT
Avalon GloboCare debuts KetoAir app on Apple App Store
News Brief: Avalon GloboCare Corp.
Avalon GloboCare shares surge as recent momentum continues
Stocks in play: Avalon GloboCare Corp.
See More Headlines
Receive ALBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.26 million
Book Value
($1.15) per share


Free Float
Market Cap
$3.17 million
Not Optionable
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. David K. Jin M.D. (Age 56)
    Ph.D., CEO, President & Director
    Comp: $330k
  • Ms. Luisa Ingargiola (Age 57)
    Chief Financial Officer
    Comp: $350k
  • Ms. Meng Li (Age 46)
    COO, Chief Marketing Officer & Secretary
    Comp: $280.24k

ALBT Stock Analysis - Frequently Asked Questions

How have ALBT shares performed in 2024?

Avalon GloboCare's stock was trading at $0.4830 on January 1st, 2024. Since then, ALBT stock has decreased by 40.9% and is now trading at $0.2855.
View the best growth stocks for 2024 here

Are investors shorting Avalon GloboCare?

Avalon GloboCare saw a increase in short interest in May. As of May 15th, there was short interest totaling 62,700 shares, an increase of 27.2% from the April 30th total of 49,300 shares. Based on an average daily volume of 183,000 shares, the short-interest ratio is presently 0.3 days. Approximately 1.3% of the company's stock are sold short.
View Avalon GloboCare's Short Interest

How were Avalon GloboCare's earnings last quarter?

Avalon GloboCare Corp. (NASDAQ:ALBT) released its quarterly earnings data on Monday, April, 15th. The company reported ($0.90) EPS for the quarter. The firm earned $0.32 million during the quarter.

When did Avalon GloboCare's stock split?

Avalon GloboCare's stock reverse split on Tuesday, January 3rd 2023. The 1-10 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Avalon GloboCare?

Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALBT) was last updated on 5/30/2024 by Staff

From Our Partners